Image of father pushing son on swing

For adults with episodic cluster headache:

Every moment without cluster headache is worth celebrating

Emgality 300 mg can help give you more cluster headache-free moments to celebrate. It's the first and only medication approved by the FDA to reduce the number of attacks.

Emgality is a prescription medicine used for the treatment of episodic cluster headache in adults.

Select Safety Information
Do not use Emgality if you are allergic to galcanezumab-gnlm or any of the ingredients in Emgality.

Hear from a real patient on Emgality 300 mg

Watch Bryan's story as he describes his journey to more cluster headache-free moments with Emgality 300 mg

Watch Now
Savings Card Image

Celebrate with the Emgality savings program*

You can get Emgality for as little as $0 for up to 12 months with the Savings Card*

Start Saving Now

To do this, we will need your HIPAA authorization to work on your behalf to help you pay as little as possible. Requesting an Emgality Savings Card shouldn’t take more than a few minutes.

*Terms and Conditions:
Offer good until 12/31/2022 for up to 12 months of Emgality. Patients that have commercial drug insurance but do not have coverage for Emgality may be able to pay as little as $0 for their first fill of Emgality. Patients that have commercial drug insurance and have coverage for Emgality may be able to pay as little as $0 per fill. Offer subject to a monthly cap and a separate annual cap. Monthly and annual caps are set at Lilly’s absolute discretion and may be changed by Lilly with or without notice. Participation in the program requires a valid patient HIPAA authorization. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or whose prescription claims for Emgality are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found here.

As a reminder, HIPAA is the Health Insurance Portability and Accountability Act that provides data privacy and security to protect your health information.

Finally, a medication approved for the treatment of episodic cluster headache that reduces the number of attacks

50% reduction data for episodic cluster headache

Emgality 300 mg cut weekly cluster headache attacks in half or more for a majority of people. 71% of people had their weekly attacks cut in half or more vs 53% of people taking placebo at Week 3.

Over the first three weeks of taking Emgality, people in a study had an average of 9 fewer attacks each week vs 5 fewer weekly attacks for people taking placebo.

Emgality 300 mg can help reduce the number of weekly cluster headache attacks so you can have more moments without cluster headache pain. Discover more about Emgality 300 mg.

Discover more


Important Facts About Emgality® (em-GAL-it-ē) injection. Also known as galcanezumab-gnlm.

Emgality is a prescription medicine used in adults for:

  • The preventive treatment of migraine. The medicine (120 mg) comes in a prefilled pen or syringe and is taken once a month.
  • The treatment of episodic cluster headache. The medicine (300 mg) comes in three (100 mg) prefilled syringes, which are taken one after the other at the start of a cluster period and then every month until the end of the cluster period.


Do not use Emgality if you are allergic to galcanezumab-gnlm or any of the ingredients in Emgality.

Emgality may cause allergic reactions, such as itching, rash, hives, and trouble breathing. Allergic reactions can happen days after using Emgality. Call your healthcare provider or get emergency medical help right away if you have any of the following symptoms, which may be part of an allergic reaction: swelling of your face, mouth, tongue, or throat, or trouble breathing.


The most common side effects of Emgality are injection site reactions.

These are not all the possible side effects of Emgality. Tell your doctor if you have any side effects.

You can report side effects at 1-800-FDA-1088 or


Before you use Emgality, discuss these questions with your doctor:

❑ Do you have other medical conditions?
❑ Do you take other medicines? Tell your doctor about all the prescription and over-the-counter drugs, vitamins, and herbal supplements you take.

Tell your doctor if:

❑ You are pregnant or breastfeeding.
Pregnancy Registry: There is a pregnancy registry for women who take EMGALITY. The purpose of this registry is to collect information about the health of you and your baby. You may enroll yourself by calling 1-833-464-4724 or by visiting or you may talk to your healthcare provider about how you can take part in this registry.
❑ You are under age 18. It is not known if Emgality is safe and effective in children.


  • Read the Instructions for Use that come with Emgality. There you will find information about how to store, prepare, and inject Emgality.
  • Use Emgality exactly as your doctor says.
  • If you miss a dose, inject it as soon as possible. Then do the following:
    • For migraine: Continue to take Emgality monthly from the date of your last dose.
    • For episodic cluster headache: If your cluster period has not ended, inject Emgality one month after your last dose to get back on a monthly dosing schedule.


For more information, go to or call 1-833-EMGALITY (1-833-364-2548).

This summary provides basic information about Emgality, but it does not include all information known about this medicine. Read the information that comes with your prescription every time you have a prescription filled. Talk to your doctor or pharmacist about this information. Your doctor is the best person to help you decide if Emgality is right for you.


Please see Instructions for Use that come with the device.